Trials / Completed
CompletedNCT01438827
Avanz Phleum Pratense Maintenance Dose
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avanz Phleum pratense | Suspension for Injection, Every 6 weeks for one year |
| DRUG | Placebo | Suspension for Injection, Every 6 weeks for one year |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-12-01
- Completion
- 2013-01-01
- First posted
- 2011-09-22
- Last updated
- 2014-01-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01438827. Inclusion in this directory is not an endorsement.